A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
Stopped Slow enrollment
Conditions
Interventions
- DRUG: NRCT-101SR, NRCT-202XR
Sponsor
Neurocentria, Inc.